fluoroloxoprofen sodium salt | 1254365-87-1

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: fluoroloxoprofen sodium salt
• 英文别名: sodium 2-(2-fluoro-4-[(2-oxocyclopentyl)methyl]phenyl)propanoate；Fluoro loxoprofen；sodium;2-[2-fluoro-4-[(2-oxocyclopentyl)methyl]phenyl]propanoate
• CAS: 1254365-87-1
• 化学式: C₁₅H₁₆FO₃*Na
• 分子量: 286.278
• InChiKey: ISLFLEUBAXYHSW-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -1.41
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  57.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-fluoroloxoprofen 在 sodium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 反应 2.0h， 以94.7%的产率得到fluoroloxoprofen sodium salt
  参考文献：
  名称：

  Properties and Synthesis of 2-{2-Fluoro (or Bromo)-4-[(2-oxocyclopentyl)methyl]phenyl}propanoic Acid: Nonsteroidal Anti-inflammatory Drugs with Low Membrane Permeabilizing and Gastric Lesion-Producing Activities

  摘要：

  We previously proposed that membrane permeabilization activity of NSAIDs is involved in NSAID-induced gastric lesions. We here synthesized derivatives of loxoprofen that have lower membrane permeabilization activity than other NSAIDs. Compared to loxoprofen, the derivatives 10a and 10b have lower membrane permeabilization activity and their oral administration produced fewer gastric lesions but showed an equivalent anti-inflammatory effect. These results suggest that 10a and 10b are likely to be therapeutically beneficial as safer NSAIDs.

  DOI：

  10.1021/jm101116s

文献信息

• Properties and Synthesis of 2-{2-Fluoro (or Bromo)-4-[(2-oxocyclopentyl)methyl]phenyl}propanoic Acid: Nonsteroidal Anti-inflammatory Drugs with Low Membrane Permeabilizing and Gastric Lesion-Producing Activities
  作者：Naoki Yamakawa、Shintaro Suemasu、Masaaki Matoyama、Ayumi Kimoto、Miho Takeda、Ken-ichiro Tanaka、Tomoaki Ishihara、Takashi Katsu、Yoshinari Okamoto、Masami Otsuka、Tohru Mizushima

  DOI：10.1021/jm101116s

  日期：2010.11.11

  We previously proposed that membrane permeabilization activity of NSAIDs is involved in NSAID-induced gastric lesions. We here synthesized derivatives of loxoprofen that have lower membrane permeabilization activity than other NSAIDs. Compared to loxoprofen, the derivatives 10a and 10b have lower membrane permeabilization activity and their oral administration produced fewer gastric lesions but showed an equivalent anti-inflammatory effect. These results suggest that 10a and 10b are likely to be therapeutically beneficial as safer NSAIDs.